Position Overview:
Sanofi Genzyme is the specialty products organization for Sanofi. Sanofi Genzyme focuses on complex disease areas where there is a significant unmet need with the goal of developing and delivering best-in-category treatments. Dupixent is a significant growth driver for Sanofi Genzyme and Sanofi organizations.
Dupixent is a monoclonal antibody targeting Type 2 inflammatory diseases by blocking IL 4 and IL 13 cytokines. These cytokines play a key role in many atopic and allergic diseases such as Atopic Dermatitis (AD), Asthma, Nasal Polyps, Eosinophilic Esophagitis, and other dermatologic and respiratory diseases. Dupixent was approved in March 2017 for the treatment of adults with moderate to severe AD and received a second approval for adolescents with AD in March 2019. Additionally, Dupixent received approval for moderate to severe Asthma in October 2018 for patients 12 years and above. The Dermatology and Respiratory indications serve as anchors for this product which is referred to as a “pipeline in a product”, due to the many indications that are approved or are being studied.
In less than 2 years since first approval, Dupixent achieved blockbuster status and requires top talent in the company to shepherd the success of this asset. The Portfolio lead will play a significant part in developing cross-indication strategies, messages and tactics to help realize the goals of this product.
The Head of US Commercial Strategy and Portfolio Marketing for Dupixent is a critical commercial leadership role contributing to the achievement of the US launch ambitions for Dupixent. He or She will develop and implement cross indication strategies and tactics in support of Dupixent in close coordination with other US stakeholders. This individual will be expected to collaborate and communicate effectively in a matrix organization with significant interactions with Brand Marketing, Patient and Provider Services, Medical, Thought Leader Liaison Leadership, Business Operations, Corporate and Business Unit Communications, Human Resources, Finance, Market Access and Senior North America Leadership. This role will have a team of 7 and will manage multiple external agencies / consultants. The individual will report to the US General Manager for Dupixent.
This position is based in Cambridge, Massachusetts.
Key Responsibilities:
Lead the development of the Dupixent cross indication franchise strategy.
Develop and lead the annual strategic planning process for the brand in conjunction with both Dermatology and Respiratory brand leads.
Develop and roll out a common approach for therapeutic area brand plans. Collaborate with the brand leads to ensure planning is completed as per the corporate timelines.
Collaborate with brand teams, agencies and across the organization to create and execute the cross indication digital/social marketing strategy. This strategy is to include patient and Health Care Provider (HCP) engagement, inclusive of multiple media channels – digital, TV, and media buy.
Play a key role in the development and implementation of the digital strategy for Dupixent.
Develop and lead Franchise internal and external communication plans and identifying innovative approaches to sharing information.
Manage manufacturing, packaging, and inventory needs of the US to ensure ample trade and sample availability for commercial use.
Lead the development and execution of the Dupixent device strategy and deployment.
Develop and execute the Franchise congress strategies. Ensure alignment with TA specific brand strategies and ensure broad overall deployment of key strategies and messages.
Manage, lead, and develop the Portfolio (Franchise) Marketing team.
Identify and leverage synergies across indications and ensure consistency in key communication messages to both internal and external stakeholders.
Partner with Sanofi Genzyme leadership to develop messages and materials for quarterly earnings.
Member of the US Dupixent Leadership Team.
Basic Qualifications:
Bachelor's degree in life sciences, marketing, finance or business required.
>10 years of relevant pharmaceutical/biotech industry experience in leadership roles.
Strong business acumen.
Ability to travel up to, and potentially in excess of, 30% of the time, including some weekends.
Strong leadership and team building skills.
Ability to lead people, timelines and work in a matrix organization in compliant and professional manner.
Experience in managing quarterly budgets.
Excellent presentation, writing, power point and organizational skills.
Experience managing external vendors.
Working knowledge of the regulatory environment.
Experience in strategic development in a multi-dimensional and rapid changing environment.
Preferred Qualifications:
MBA Preferred.
Dermatology, Respiratory, or Biologic Launch experience is a plus.
Alliance experience is a plus.
Cambridge, MA
As the specialty care global business unit of Sanofi, we are focused on rare diseases, rare blood disorders, multiple sclerosis, oncology and immunology. More than 30 years since we began, we remain just as committed to and passionate about advancing therapies that offer hope to patients and families.
Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world’s leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing.
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology. In 2018, with the acquisitions of Bioverativ and Ablynx, we further expanded our focus to include rare blood disorders, bringing deep expertise in hematology.
Our ambition is to be the industry leader in specialty care. We currently provide more than 25 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.
Driven by our commitment to patients, we strive to develop strong relationships with our patient communities, listening to their perspectives so that we can truly understand their needs. These collaborations continue to guide and motivate us as we work to push the boundaries of medicine and technology to develop new and better therapies where none existed before.